A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers

Peer Review reports

Original Submission
28 Aug 2018	Submitted	Original manuscript
18 Oct 2018	Reviewed	Reviewer Report - Peter Lichtlen
23 Oct 2018	Reviewed	Reviewer Report - Qi Zhao
19 Nov 2018	Author responded	Author comments - Tracy L Staton
Resubmission - Version 2
19 Nov 2018	Submitted	Manuscript version 2
23 Nov 2018	Reviewed	Reviewer Report - Peter Lichtlen
30 Nov 2018	Author responded	Author comments - Tracy L Staton
Resubmission - Version 3
30 Nov 2018	Submitted	Manuscript version 3
Publishing
10 Dec 2018	Editorially accepted
7 Jan 2019	Article published	10.1186/s12890-018-0763-9

Back to article page